Hello Friends! Are you looking to invest in the stock market, or have you already invested? Would you like to know the predictions regarding the potential fluctuations in your shares? If so, you have landed on exactly the right page. On this page, you will find information regarding Corona Remedies share price screener, Corona Remedies Share Price Moneycontrol, Corona Remedies share price IPO, Corona remedies share price prediction, Corona Remedies Share price target 2026, Corona Remedies share price NSE today, and much more. Furthermore, this page provides details on Corona Remedies‘s share price targets 2026, 2027, 2028, 2029, 2030, 2040, and beyond.
Corona Remedies Company Information
| Founded | 2004 |
| Headquarters | India |
| Number of employees | 4,500 (2025) |
Corona Remedies Share Price Target Overview
- Current Price – 1,672.60
- Open – 1,692.00
- High – 1,692.00
- Low – 1,665.00
- Mkt cap – 10.23KCr
- P/E ratio – 55.28
- 52-wk high – 1,949.40
- 52-wk low – 1,336.60
- Dividend – 0.60%
- Qtrly div amt – 2.51
Corona Remedies Share Price Chart
Corona Remedies Share Price Target Tomorrow (Prediction)
| Corona Remedies Share Price Target Years | Corona Remedies Share Price Target |
| 2026 | ₹2000 |
| 2027 | ₹2250 |
| 2028 | ₹2500 |
| 2029 | ₹2750 |
| 2030 | ₹3000 |
Corona Remedies Share Price Target 2026
The target for Corona Remedies’s share price in 2026 is projected to range between ₹1950 and ₹2000. As of the start of June 2026, Corona Remedies’s share price stood at ₹1,672.60. Compared to the previous year, Corona Remedies’s share price has witnessed an increase this year.
Corona Remedies Share Price Target 2027
The target for Corona Remedies’s share price in 2027 is projected to range between ₹2200 and ₹2250. On 01 June 2026, Corona Remedies Share price NSE is 1,672.60 INR. Compared to last year, no significant difference has been observed in the share price of Corona Remedies. The share price has increased by approximately 240-250 rupees.
Corona Remedies Share Price Target 2030
The target for Corona Remedies’s share price in 2030 is projected to range between ₹2950 and ₹3000. Over the past several years, the company has generated substantial profits, and investors, too, have earned handsome returns proportionate to their shareholdings. We remain optimistic that the company will continue to generate profits in the future, thereby ensuring continued returns for its investors.
Read Also:- Emcure Pharma Share Price Target Tomorrow From 2026 to 2030 – Current Chart, Market Overview
Corona Remedies Shareholding Pattern
| Promoter | 69% |
| FII | 22.01% |
| DII | 0.67% |
| Retails & Others | 1.98% |
| Mutual Funds | 6.35% |
Income Statement Of Corona Remedies
|
All values in INR
|
Jun 2025
|
Sep 2025
|
Dec 2025
|
Mar 2026
|
|---|---|---|---|---|
|
Revenue
|
3.47B
|
3.61B
|
3.42B
|
3.53B
|
|
Cost of goods sold
|
673.91M
|
686.50M
|
602.70M
|
662.40M
|
|
Cost of revenue
|
673.91M
|
686.50M
|
602.70M
|
662.40M
|
|
Research and development expenses
|
–
|
–
|
–
|
–
|
|
Total research and development expenses
|
–
|
–
|
–
|
–
|
|
Selling, general, and admin expenses
|
1.24B
|
1.03B
|
959.40M
|
1.07B
|
|
Operating expense
|
2.18B
|
2.23B
|
2.08B
|
2.35B
|
|
Total operating expenses
|
2.86B
|
2.92B
|
2.69B
|
3.01B
|
|
Operating income
|
610.30M
|
692.70M
|
737.10M
|
517.30M
|
|
Other non operating income
|
2.79M
|
22.70M
|
22.40M
|
41.10M
|
|
EBT including unusual items
|
606.93M
|
697.80M
|
552.10M
|
547.40M
|
|
EBT excluding unusual items
|
608.38M
|
697.80M
|
743.10M
|
547.40M
|
|
Income tax expense
|
144.97M
|
174.60M
|
139.40M
|
94.10M
|
|
Effective tax rate
|
23.89%
|
25.02%
|
25.25%
|
17.19%
|
|
Other operating expenses
|
855.24M
|
1.11B
|
1.03B
|
1.18B
|
|
Net income
|
461.96M
|
523.20M
|
412.70M
|
453.30M
|
|
Net profit margin
|
13.33%
|
14.49%
|
12.05%
|
12.84%
|
|
Earnings per share
|
–
|
–
|
–
|
7.41
|
|
Interest and investment income
|
14.57M
|
–
|
–
|
–
|
|
Interest expense
|
-19.37M
|
-19.30M
|
-16.60M
|
-13.80M
|
|
Net interest expenses
|
-4.80M
|
-19.30M
|
-16.60M
|
-13.80M
|
|
Depreciation and amortization charges
|
89.18M
|
92.00M
|
94.50M
|
102.90M
|
|
EBITDA
|
690.04M
|
794.16M
|
838.56M
|
611.98M
|
|
Gain or loss from assets sale
|
1.69M
|
2.61M
|
–
|
–
|
Read Also:- Ajanta Pharma Share Price Target Tomorrow From 2026 to 2030 – Current Chart, Market Overview
Hi, I’m Ronak, a news writer covering the latest updates in automobiles, education, smartphones, and trending topics. I focus on delivering simple, clear, and timely news to keep readers informed about what’s happening around the world.